Josh Hexter, Chief Operating Officer of Oramed Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems including what would be the first oral formulation of insulin joins eHealth Radio and the Diabetes, Pharmaceutical, & Health News Channels.
- Many listeners may be familiar with diabetes, either they are affected or know a family member affected by the condition. Can you explain to our listeners the differences between the Type I and II diabetes? What toll does this disease create?
- What role does insulin play in diabetes?
- Why has it taken so long for researchers to turn insulin into a pill? What has been the challenges?
- Your company is working on an oral version of insulin. Can you describe how does it work and what stage are you in drug’s development?
- Can you explain why treating patients who may be at risk for Type II diabetes (prediabetes) with Oramed’s oral pill? What protection does the oral version of insulin provide?
Mr. Hexter serves as Chief Operating Officer and Vice President of Business Development of Oramed Pharmaceuticals, which he joined in 2013. He brings to Oramed more than 15 years of prominent leadership, business development, operations know-how and management in the life science sector. He was most recently Executive Director of Corporate In-Licensing at BioLineRx Prior to joining BioLineRx, he worked in private equity and venture capital where he served as CEO of a VC-backed startup.
As CEO of Biosensor Systems Design, Mr. Hexter was instrumental in shaping the company’s strategic focus and in forging business development agreements with Fortune 100 companies in the areas of food safety, medical diagnostics and homeland security. Mr. Hexter earned a bachelor’s degree from the University of Wisconsin and a master’s degree in management from Boston University.